Bad Precedent? Plan B Rx/OTC Labeling May Have Implications For Existing OTCs ­– NEJM
This article was originally published in The Pink Sheet Daily
Nonprescription drugs, such as aspirin and ibuprofen, could be reevaluated if Barr chooses simultaneous Rx/OTC marketing of levonorgestrel at the same dose for both populations.
You may also be interested in...
Barr will have to detail a mechanism for drugstores to screen women less than 16 years of age for nonprescription use of the emergency contraceptive. FDA's decision goes against the recommendation of its advisory panels.
Modification to ‘reasonable and necessary’ definition in MCIT final rule offers new avenue for drug manufacturers to get products covered in Part B. The Biden Administration will have to decide whether it will keep the Trump regulation unchanged.
The intensely negative advisory committee for Biogen’s proposed Alzheimer’s therapy was a shocker. Would it have happened if US FDA had been able to convene an in-person event instead of a ‘virtual’ one?